CDI-988 — Topline data
Q4 2026
We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026, and we're grateful for OPKO's continued conviction in the value of our lead asset, CDI-988, and our broader antiviral pipeline spanning influenza, coronaviruses and hepatitis C.Source filing